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Approximately 2.7 million Americans have active Hepa-
titis C infection. Combination therapy with ribavirin and
interferon alfa-2b has emerged as the treatment of choice
for Hepatitis C. OBJECTIVES: To determine if the pre-
scribing of combination therapy differed among ethnic
groups in Hepatitis C-infected members during calendar
year 1999 in a Medicaid MCO. METHODS: Hepatitis
C-infected patients were identified from a database of
continuously enrolled members of an inner-city Medicaid
MCO in Philadelphia using ICD-9 codes indicative of
Hepatitis C (070.41, 070.44, 070.51, 070.54, 571.40,
571.41, V02.60, V02.62). From this population, mem-
bers who received combination therapy with ribavirin
and interferon alfa-2b were identified and demographic
information was obtained. Variation in the prescribing of
combination therapy among ethnic groups was assessed
using a Chi-square test. RESULTS: From a cohort of
73,869 members, 395 members (0.535%) had an ICD-9
code for Hepatitis C. Of those, 60 members had phar-
macy claims for combination therapy during 1999. These
members aged from 23 to 64 years (mean age  45.0 yrs;
SD  7.6). Based on the ethnic distribution of the 395
members with an ICD-9 code for Hepatitis C, 8.4% (16/
191) of African-Americans were prescribed combination
therapy compared with 23% (28/122) of Caucasians,
22.7% (15/66) of Latinos and 14.3% (1/7) of Asian-
Americans. A statistically significant difference in the pre-
scribing of combination therapy was noted among ethnic
groups (p  0.05). CONCLUSIONS: Within this Medic-
aid MCO, a disproportionately low percentage of Afri-
can–American members received combination therapy
for Hepatitis C during 1999. It is unknown whether this
was due to a disproportionate number of contraindica-
tions in this group, inequitable prescribing habits of phy-
sicians, cultural barriers preventing consent for treat-
ment, or noncompliance with obtaining the medication.
Further investigation is needed to determine why this dis-
parity exists so that differences in treatment among eth-
nic groups may be minimized.
HP2
THE ROLE OF OUTLIER PAYMENTS IN 
MEDICARE PATIENTS WITH SEVERE SEPSIS
Cooper LM1, Linde-Zwirble WT2
1Eli Lilly and Company, Indianapolis, IN, USA; 2Health Process 
Management, Owings Mills, MD, USA
INTRODUCTION: Medicare is required to set outlier
threshold so that outlier payments are between 5 and 6
percent of total DRG payments to offset extraordinarily
high-cost cases. Severe sepsis (SS) is a condition affecting
patients in many DRGs. High mortality and resource use
in SS patients increases the likelihood of reimbursement
under the outlier mechanism. We explore the role of out-
lier payments for SS in Medicare. METHODS: We exam-
ined all 1999 Medicare discharges age 65 in prospec-
tive payment hospitals. Cost, reimbursement, and outlier
payments were identified for each discharge. SS was iden-
tified by the presence of ICD-9-CM codes for acute organ
failure and bacterial or fungal infection. DRGs were clas-
sified into six groups by post-operative status (medical
and surgical) and by frequency of SS (high risk, high vol-
ume, remaining). RESULTS: Of 9,248,277 records,
384,680 (4%) were reimbursed through the outlier mech-
anism, reflecting 6% of total payments. SS patients repre-
sent 25% of all outliers, with an average cost per outlier
case of $44,724. The average cost for non-sepsis outliers
per case is $35,098. Twenty-two percent of all sepsis
cases are reimbursed as outliers. While overall cases are
reimbursed at 95% of reported costs, SS cases are reim-
bursed at only 85% of costs. SS outliers are reimbursed
at only 70% of reported costs with especially low reim-
bursements for high volume medical SS outlier cases
(54%). Overall, SS high risk medical and surgical cases
are reimbursed at higher levels (103% and 78% respec-
tively). CONCLUSIONS: While severe sepsis cases are
only 4.7% of all Medicare discharges, almost one in four
are outliers. Current outlier payments do not adequately
compensate for the cost of care of most SS patients.
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BACKGROUND: In January 1998, Regence BlueShield,
a 1.2 million-member health plan, implemented a novel
formulary submission process intended to improve clini-
cal decision-making. The process requires pharmaceutical
manufacturers to submit dossiers that include clinical and
health outcomes data as well as an economic model that
will demonstrate the impact of introducing the product
to the health plan. Since implementation, the process has
not been evaluated. OBJECTIVE: To evaluate the scope
and content of submission dossiers received from January
1998 to June 2000. METHODS: All dossiers received
from January 1998 to June 2000 were collected and re-
viewed. They were evaluated for compliance with the Re-
gence Formulary Submission Guidelines. Data were en-
tered into a spreadsheet for analysis. RESULTS: A total
of 50 dossiers were reviewed. 25 (50%) were received in
year 1, 16 (32%) in year 2, and 9 (18%) in the first six
months of year 3. An economic model was provided in
31 dossiers, increasing from 55% to 78% of dossiers
over the three years. Only 10 models were cost-effective-
ness analyses. The remaining models were budget impact
analyses. Complete clinical information was included in
48%, 63% and 78% of submissions in years 1, 2 and 3
respectively. Dossiers were prepared by one of three
sources: Staff at the manufacturer’s headquarters (68%),
an outside vendor (10%) or a local manufacturer’s repre-
sentative (22%). Unpublished studies, which were specif-
